FDA announces Biosimilars Action Plan; industry applauds plan
In an effort to advance paths to competition for biologics from biosimilars and to reduce costs for patients and our health care system, the Food and Drug Administration announced its Biosimilars Action Plan, a part of the Trump administrations’ Blueprint to Lower Drug Prices.